Abstract | OBJECTIVE: METHODS: In this prospective, 120 early DN patients aged 20-75 years from the Endocrinology Department of Chengyang District People's Hospital of Qingdao City in 2015 were randomized to intervention group including 68 patients and control group including 52 patients. Two groups of patients separately received Epalrestat and placebo for 3 months. Renal vascular parameters and blood biochemical index were collected at baseline and after intervention. RESULTS: CONCLUSION:
Epalrestat can effectively improve renal arterial blood flow and renal arterial perfusion, which play a protective role in early DN.
|
Authors | Mingxia Liu, Fangfang Li, Mei Liang, Xiaopang Rao |
Journal | Journal of diabetes and its complications
(J Diabetes Complications)
Vol. 34
Issue 9
Pg. 107620
(09 2020)
ISSN: 1873-460X [Electronic] United States |
PMID | 32444327
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2020 Elsevier Inc. All rights reserved. |
Chemical References |
- Enzyme Inhibitors
- Aldehyde Reductase
|
Topics |
- Adult
- Aged
- Aldehyde Reductase
(antagonists & inhibitors)
- China
- Diabetes Mellitus
- Diabetic Nephropathies
(drug therapy)
- Enzyme Inhibitors
(therapeutic use)
- Humans
- Kidney
(blood supply)
- Middle Aged
- Prospective Studies
- Renal Circulation
- Young Adult
|